Endothelial function in HIV-infected patients with low or mild cardiovascular risk

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 1, 2006, Pages 133-139

  Blanco, Juan José Ríos ^a   García, Inés Suárez ^a   Cerezo, Jorge Gómez ^a   de Rivera, José ^a   Anaya, Pilar Moreno ^a   Raya, Pilar García ^a   García, Juan González ^a   López, José Ramón Arribas ^a   Hernández, Francisco Javier Barbado ^a   Rodríguez, Juan José Vázquez ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Antiretroviral therapy; Atherosclerosis; Risk factors

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; VIRUS RNA;

ADULT; ANGIOGRAPHY; ARTERY DILATATION; ARTICLE; BRACHIAL ARTERY; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY RISK; ENDOTHELIUM LESION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; STATISTICAL SIGNIFICANCE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; VASODILATION;

EID: 33748209571     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl190     Document Type: Article

References (43)

1. Murphy EL, Collier AC, Kalish LA et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135: 17-26.
2. Behrens G, Dejam A, Schmidt H et al. Impaired glucose tolerance, β cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13: F63-70.
3. Nolan D. Metabolic complications associated with HIV protease inhibitor therapy. Drugs 2003; 63: 2555-74.
4. Saves M, Chene G, Ducimetiere P et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37: 292-8.
5. Tanwani LK, Mokshagundam SL. Lipodystrophy, insulin resistance, diabetes mellitus, dyslipidemia, and cardiovascular disease in human immunodeficiency virus infection. South Med J 2003; 96: 180-8.
6. Friis-Moller N, Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 1179-93.
7. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352: 48-62.
8. Passalaris JD, Sepkowitz KA, Glesby MJ. Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis 2000; 31: 787-97.
9. Rhew DC, Bernal M, Aguilar D et al. Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: A systematic review. Clin Infect Dis 2003; 37: 959-72.
10. Barthelemy O, Escaut L, Vayre F et al. Acute coronary syndromes in patients treated with HIV protease inhibitors. Presse Med 2002; 31: 343-8.
11. Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
12. Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-5.
13. Gomez-Cerezo J, Rios Blanco JJ, Suarez Garcia I et al. Noninvasive study of endothelial function in white coat hypertension. Hypertension 2002; 40: 304-9.
14. Landmesser U, Hornig B, Drexler H. Endothelial dysfunction in hypercholesterolemia: Mechanisms, pathophysiological importance, and therapeutic interventions. Semin Thromb Hemost 2000; 26: 529-37.
15. Panza JA, Quyyumi AA, Brush JE Jr et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-7.
16. Dogra G, Rich L, Stanton K et al. Endothelium-dependent and independent vasodilation studies at normoglycaemia in type I diabetes mellitus with and without microalbuminuria. Diabetologia 2001; 44: 593-601.
17. Stein JH, Klein MA, Bellehumeur JL et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104: 257-62.
18. Nolan D, Watts GF, Herrmann SE et al. Endothelial function in HIV-infected patients receiving protease inhibitor therapy: Does immune competence affect cardiovascular risk? QJM 2003; 96: 825-32.
19. Bonnet D, Aggoun Y, Szezepanski I et al. Arterial stiffness and endothelial dysfunction in HIV-infected children. AIDS 2004; 18: 1037-41.
20. Anon. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-46.
21. Anon. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19: 1434-503.
22. Kamps BS, Brodt HR, Staszewski S et al. AIDS-free survival and overall survival in HIV infection: The new CDC classification system (1993) for HIV disease and AIDS. Clin Investig 1994; 72: 283-7.
23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
24. Corretti MC, Anderson TJ, Benjamin EJ et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-65.
25. Schroeder S, Enderle MD, Ossen R et al. Noninvasive determination of endothelium-mediated vasodilation as a screening test for coronary artery disease: Pilot study to assess the predictive value in comparison with angina pectoris, exercise electrocardiography, and myocardial perfusion imaging. Am Heart J 1999; 138: 731-9.
26. Takase B, Uehata A, Akima T et al. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol 1998; 82: 1535-8.
27. Sorensen KE, Celermajer DS, Spiegelhalter DJ et al. Non-invasive measurement of human endothelium dependent arterial responses: Accuracy and reproducibility. Br Heart J 1995; 74: 247-53.
28. Bots ML, Westerink J, Rabelink TJ et al. Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: Effects of technical aspects of the FMD measurement on the FMD response. Eur Heart J 2005; 26: 363-8.
29. Norata GD, Pirillo A, Callegari E et al. Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL. Cardiovasc Res 2003; 59: 169-80.
30. Celermajer DS, Sorensen KE, Spiegelhalter DJ et al. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 1994; 24: 471-6.
31. Gerhard M, Roddy MA, Creager SJ et al. Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. Hypertension 1996; 27: 849-53.
32. Giordano G, Guarini P, Giordano A et al. Reduced endothelium-dependent peripheral vasodilation in the aged. Cardiologia 1995; 40: 47-50.
33. Andrawis N, Jones DS, Abernethy DR. Aging is associated with endothelial dysfunction in the human forearm vasculature. J Am Geriatr Soc 2000; 48: 193-8.
34. Riddler SA, Smit E, Cole SR et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289: 2978-82.
35. Benfield T. Hepatitis C in the EuroSIDA Cohort of European HIV infected patients. Prevalence and prognostic value. In: Abstracts of the Twelfth World AIDS Conference, Geneva, 1998. Abstract 22261. Int Conf AIDS 1998; 12: 222.
36. Solages A, Thornton D, Ray P et al. Influence of HIV infection and hepatitis C on endothelial function In: Abstracts of the Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2004. Abstract 730. Foundation for Retrovirology and Human Health, Alexandria, VA, USA. http://retroconference.org/2004/cd/Abstract/730.htm.
37. Mikhail N. Insulin resistance in HIV-related lipodystrophy. Curr Hypertens Rep 2003; 5: 117-21.
38. de Larranaga GF, Petroni A, Deluchi G et al. Viral load and disease progression as responsible for endothelial activation and/or injury in human immunodeficiency virus-1-infected patients. Blood Coagul Fibrinolysis 2003; 14: 15-8.
39. Chi D, Henry J, Kelley J et al. The effects of HIV infection on endothelial function. Endothelium 2000; 7: 223-42.
40. Lafeuillade A, Alessi MC, Poizot-Martin I et al. Endothelial cell dysfunction in HIV infection. J Acquir Immune Defic Syndr 1992; 5: 127-31.
41. Paton P, Tabib A, Loire R et al. Coronary artery lesions and human immune deficiency virus infection. Res Virol 1993; 144: 225-31.
42. Conklin BS, Fu W, Lin PH et al. HIV protease inhibitor ritonavir decreases endothelium-dependent vasorelaxation and increases superoxide in porcine arteries. Cardiovasc Res 2004; 63: 168-75.
43. Sklar P, Masur H. HIV infection and cardiovascular disease-is there really a link? N Engl J Med 2003; 349: 2065-7.